Drug Type Universal CAR-T |
Synonyms Allo-RevCAR01-T + R-TM123 + [1] |
Target |
Mechanism CD123 modulators(Interleukin-3 receptor subunit alpha modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization AvenCell Europe GmbHStartup |
Active Organization AvenCell Europe GmbHStartup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory acute myeloid leukemia | Phase 1 | NL | AvenCell Europe GmbHStartup | 03 Jan 2024 |
Refractory acute myeloid leukemia | Phase 1 | DE | AvenCell Europe GmbHStartup | 03 Jan 2024 |
Relapsing acute myeloid leukemia | Phase 1 | NL | AvenCell Europe GmbHStartup | 03 Jan 2024 |
Relapsing acute myeloid leukemia | Phase 1 | DE | AvenCell Europe GmbHStartup | 03 Jan 2024 |